Search

Your search keyword '"NiChonghaile, M."' showing total 8 results
Start Over Author "NiChonghaile, M."
8 results on '"NiChonghaile, M."'

1. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group

Author

Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A.S., Aljurf, M., Arat, M., Bader, P., Baron, F., Basak, G., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J.H., Dignan, F., Fukuda, T., Huynh, A., Kuball, J., Lachance, S., Lazarus, H., Masszi, T., Michallet, M., Nagler, A., NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F.B., Richardson, P.G., Ruutu, T., Saber, W., Savani, B.N., Soiffer, R., Styczynski, J., Wallhult, E., Yakoub-Agha, I., Duarte, R.F., Carreras, Enric, Universitat Autònoma de Barcelona, HUS Comprehensive Cancer Center, Clinicum, Hematologian yksikkö, Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Basak, G., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. -H., Dignan, F., Fukuda, T., Huynh, A., Kuball, J., Lachance, S., Lazarus, H., Masszi, T., Michallet, M., Nagler, A., Nichonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Saber, W., Savani, B. N., Soiffer, R., Styczynski, J., Wallhult, E., Yakoub-Agha, I., Duarte, R. F., Carreras, E., and UAM. Departamento de Medicina

Subjects
Feature, Adult, medicine.medical_specialty, HEPATIC VENOOCCLUSIVE DISEASE, HAPLOIDENTICAL DONOR TRANSPLANTATION, Medicina, 3122 Cancers, Hepatic Veno-Occlusive Disease, Disease, Hematopoietic cell transplantation (HCT), Therapeutics, PERIPHERAL-BLOOD, law.invention, 03 medical and health sciences, 0302 clinical medicine, Polydeoxyribonucleotides, Randomized controlled trial, law, medicine, Humans, Vascular Diseases, Intensive care medicine, Transplantation, Adult patients, business.industry, Mortality rate, Consensus guideline, Hematopoietic Stem Cell Transplantation, REGIMEN-RELATED TOXICITIES, STEM-CELL TRANSPLANTATION, Hematology, Expert group, BONE-MARROW-TRANSPLANTATION, PD-1 BLOCKADE, EUROPEAN-SOCIETY, RANDOMIZED-TRIAL, 3. Good health, URSODEOXYCHOLIC ACID, 030220 oncology & carcinogenesis, Veno-occlusive disease (SOS/VOD, Veno-Occlusive Disease, Complication, business, Haematological diseases, 030215 immunology
Abstract

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). While SOS/VOD may resolve within a few weeks in the majority of patients with mild-to-moderate disease, the most severe forms result in multiorgan dysfunction and are associated with a high mortality rate (>80%). Therefore, careful surveillance may allow early detection of SOS/VOD, particularly as the licensed available drug is proven to be effective and reduce mortality. The aim of this work is to propose an international consensus guideline for the treatment and prevention of SOS/VOD in adult patients, on behalf of an international expert group, This work was made possible thanks to the support of the Association for Training, Education, Research, in Hematology, Immunology and Transplantation (ATHERIT), which received an unrestricted educational grant from JAZZ pharmaceuticals

Published
2021

2. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Duarte, R F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Pagluica, T, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, and Carreras, E

Published
2015
Full Text
View/download PDF

3. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients

Author

University of Helsinki, Department of Medicine, Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J-H, Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A., NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F., Carreras, E., University of Helsinki, Department of Medicine, Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J-H, Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A., NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F., and Carreras, E.

Abstract

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate (480%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be effective and licensed for its treatment. Unfortunately, current criteria lack sensitivity and specificity, making early identification and severity assessment of SOS/VOD difficult. The aim of this work is to propose a new definition for diagnosis, and a severity-grading system for SOS/VOD in adult patients, on behalf of the European Society for Blood and Marrow Transplantation.

Published
2016

4. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

Author

Mohty, M, primary, Malard, F, additional, Abecassis, M, additional, Aerts, E, additional, Alaskar, A S, additional, Aljurf, M, additional, Arat, M, additional, Bader, P, additional, Baron, F, additional, Bazarbachi, A, additional, Blaise, D, additional, Ciceri, F, additional, Corbacioglu, S, additional, Dalle, J-H, additional, Dignan, F, additional, Fukuda, T, additional, Huynh, A, additional, Masszi, T, additional, Michallet, M, additional, Nagler, A, additional, NiChonghaile, M, additional, Okamoto, S, additional, Pagliuca, A, additional, Peters, C, additional, Petersen, F B, additional, Richardson, P G, additional, Ruutu, T, additional, Savani, B N, additional, Wallhult, E, additional, Yakoub-Agha, I, additional, Duarte, R F, additional, and Carreras, E, additional

Published
2016
Full Text
View/download PDF

5. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

Author

Mauricette Michallet, Takahiro Fukuda, Peter Bader, Ahmed Alaskar, Paul G. Richardson, C Peters, Mutlu Arat, Bipin N. Savani, Finn Bo Petersen, Erik Aerts, Tapani Ruutu, J.-H. Dalle, Fiona L Dignan, Fabio Ciceri, M. Abecassis, Mairead NiChonghaile, M. Mohty, Selim Corbacioglu, Arnon Nagler, E. Wallhult, S. Okamoto, Tamás Masszi, Didier Blaise, Florent Malard, R. F. Duarte, Anne Huynh, M Aljurf, Ali Bazarbachi, Enric Carreras, Ibrahim Yakoub-Agha, Frédéric Baron, A Pagliuca, Department of Medicine, Clinicum, Department of Oncology, Mohty, M, Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, Fabio, Corbacioglu, S., Dalle, J. H., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A., Nichonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub Agha, I., Duarte, R. F., Carreras, E., and UAM. Departamento de Medicina

Subjects
Pediatrics, Veno-occlusive disease, medicine.medical_treatment, Hepatic Veno-Occlusive Disease, Hematopoietic stem cell transplantation, Disease, Defibrotide, Severity of Illness Index, 0302 clinical medicine, Risk Factors, Diagnosis, VERSUS-HOST-DISEASE, Medicine, HIGH-RISK POPULATION, MR-IMAGING FINDINGS, Sinusoidal obstruction syndrome, Mortality rate, Hematopoietic Stem Cell Transplantation, Hematology, 3. Good health, 030220 oncology & carcinogenesis, medicine.drug, Adult, medicine.medical_specialty, Hepatic veno-occlusive disease, Patients, Medicina, 3122 Cancers, Sensitivity and Specificity, 03 medical and health sciences, CONDITIONING REGIMEN, VENOCCLUSIVE DISEASE, Severity of illness, Humans, Special Report, TISSUE-PLASMINOGEN ACTIVATOR, Transplantation, HEPATIC VENOOCCLUSIVE-DISEASE, business.industry, STEM-CELL TRANSPLANTATION, medicine.disease, Surgery, Early Diagnosis, MULTIORGAN FAILURE, bacteria, Complication, business, SIGNIFICANT TOXICITY, Biomarkers, 030215 immunology
Abstract

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate ( > 80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be effective and licensed for its treatment. Unfortunately, current criteria lack sensitivity and specificity, making early identification and severity assessment of SOS/VOD difficult. The aim of this work is to propose a new definition for diagnosis, and a severity-grading system for SOS/VOD in adult patients, on behalf of the European Society for Blood and Marrow Transplantation., FM was supported by educational grants from the 'Association for Training, Education and Research in Hematology, Immunology and Transplantation' (ATERHIT, Nantes, France)

Published
2016
Full Text
View/download PDF

6. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Fabio Ciceri, Tapani Ruutu, Mairead NiChonghaile, Anne Huynh, Enric Carreras, Ibrahim Yakoub-Agha, P. G. Richardson, As. Alaskar, C Peters, M. Abecassis, B.N. Savani, M. Mohty, Selim Corbacioglu, Tamás Masszi, J.-H. Dalle, Mutlu Arat, Takahiro Fukuda, Peter Bader, Frédéric Baron, M Aljurf, Ali Bazarbachi, Florent Malard, Arnon Nagler, Fb. Petersen, Elisabeth Wallhult, Didier Blaise, R. F. Duarte, T. Pagluica, Erik Aerts, Mauricette Michallet, Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, Fabio, Corbacioglu, S, Dalle, Jh, Duarte, Rf, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, Nichonghaile, M, Pagluica, T, Peters, C, Petersen, Fb, Richardson, Pg, Ruutu, T, Savani, Bn, Wallhult, E, Yakoub Agha, I, and Carreras, E.

Subjects
Position statement, Adult, medicine.medical_specialty, medicine.medical_treatment, genetic processes, Hematopoietic stem cell transplantation, Disease, Defibrotide, Postoperative Complications, Risk Factors, medicine, Humans, Vascular Diseases, Prospective cohort study, Intensive care medicine, Special Report, Transplantation, Marrow transplantation, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, biochemical phenomena, metabolism, and nutrition, enzymes and coenzymes (carbohydrates), surgical procedures, operative, bacteria, Veno-Occlusive Disease, Complication, business, Biomarkers, medicine.drug
Abstract

Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of hematopoietic SCT (HSCT). This review aims to highlight, on behalf of the European Society for Blood and Marrow Transplantation, the current knowledge on SOS/VOD pathophysiology, risk factors, diagnosis and treatments. Our perspectives on SOS/VOD are (i) to accurately identify its risk factors; (ii) to define new criteria for its diagnosis; (iii) to search for SOS/VOD biomarkers and (iv) to propose prospective studies evaluating SOS/ VOD prevention and treatment in adults and children.

Published
2015

7. A pilot feasibility randomised controlled trial of bone antiresorptive agents on bone turnover markers in critically ill women.

Author

Orford NR, Bone A, Kotowicz MA, Bailey M, Pasco JA, Maiden M, Kakho N, Cattigan C, Nichonghaile M, Jones C, Hodgson C, Nair P, Center J, and Bellomo R

Subjects
Humans, Female, Critical Illness, Denosumab, Feasibility Studies, Pandemics, Bone Remodeling, Bone Density Conservation Agents therapeutic use
Abstract

Critical illness is associated with increased bone turnover, loss of bone density, and increased risk of fragility fractures. The impact of bone antiresorptive agents in this population is not established. This trial examined the efficacy, feasibility, and safety of antiresorptive agents administered to critically ill women aged fifty years or greater. Women aged 50 years or greater admitted to an intensive care unit for at least 24 h were randomised to receive an antiresorptive agent (zoledronic acid or denosumab) or placebo, during critical illness and six months later (denosumab only). Bone turnover markers and bone mineral density (BMD) were monitored for 1 year. We studied 18 patients over 35 months before stopping the study due to the COVID-19 pandemic. Antiresorptive medications decreased the bone turnover marker type 1 cross-linked c-telopeptide (CTX) from day 0 to 28 by 43% (± 40%), compared to an increase of 26% (± 55%) observed with placebo (absolute difference - 69%, 95% CI - 127% to - 11%), p = 0.03). Mixed linear modelling revealed differences in the month after trial drug administration between the groups in serum CTX, alkaline phosphatase, parathyroid hormone, and phosphate. Change in BMD between antiresorptive and placebo groups was not statistically analysed due to small numbers. No serious adverse events were recorded. In critically ill women aged 50-years and over, antiresorptive agents suppressed bone resorption markers without serious adverse events. However, recruitment was slow. Further phase 2 trials examining the efficacy of these agents are warranted and should address barriers to enrolment.Trial registration: ACTRN12617000545369, registered 18th April 2017., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

8. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.

Author

Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Basak G, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Kuball J, Lachance S, Lazarus H, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Saber W, Savani BN, Soiffer R, Styczynski J, Wallhult E, Yakoub-Agha I, Duarte RF, and Carreras E

Subjects
Adult, Humans, Polydeoxyribonucleotides, Hematopoietic Stem Cell Transplantation, Hepatic Veno-Occlusive Disease etiology, Hepatic Veno-Occlusive Disease prevention & control, Vascular Diseases
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results